Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System
- PMID: 35040965
- PMCID: PMC8767437
- DOI: 10.1001/jamanetworkopen.2021.44027
Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System
Erratum in
-
Errors in Abstract and Results.JAMA Netw Open. 2022 Feb 1;5(2):e222773. doi: 10.1001/jamanetworkopen.2022.2773. JAMA Netw Open. 2022. PMID: 35188559 Free PMC article. No abstract available.
Abstract
Importance: Prostate cancer (PCa) disproportionately affects African American men, but research evaluating the extent of racial and ethnic disparities across the PCa continuum in equal-access settings remains limited at the national level. The US Department of Veterans Affairs (VA) Veterans Hospital Administration health care system offers a setting of relatively equal access to care in which to assess racial and ethnic disparities in self-identified African American (or Black) veterans and White veterans.
Objective: To determine the extent of racial and ethnic disparities in the incidence of PCa, clinical stage, and outcomes between African American patients and White patients who received a diagnosis or were treated at a VA hospital.
Design, setting, and participants: This retrospective cohort study included 7 889 984 veterans undergoing routine care in VA hospitals nationwide from 2005 through 2019 (incidence cohort). The age-adjusted incidence of localized and de novo metastatic PCa was estimated. Treatment response was evaluated, and PCa-specific outcomes were compared between African American veterans and White veterans. Residual disparity in PCa outcome, defined as the leftover racial and ethnic disparity in the outcomes despite equal response to treatment, was estimated.
Exposures: Self-identified African American (or Black) and White race and ethnicity.
Main outcomes and measures: Time to distant metastasis following PCa diagnosis was the primary outcome. Descriptive analyses were used to compare baseline demographics and clinic characteristics. Multivariable logistic regression was used to evaluate race and ethnicity association with pretreatment clinical variables. Multivariable Cox regression was used to estimate the risk of metastasis.
Results: Data from 7 889 984 veterans from the incidence cohort were used to estimate incidence, whereas data from 92 269 veterans with localized PCa were used to assess treatment response. Among 92 269 veterans, African American men (n = 28 802 [31%]) were younger (median [IQR], 63 [58-68] vs 65 [62-71] years) and had higher prostate-specific antigen levels (>20 ng/mL) at the time of diagnosis compared with White men (n = 63 467; [69%]). Consistent with US population-level data, African American veterans displayed a nearly 2-fold greater incidence of localized and de novo metastatic PCa compared with White men across VA centers nationwide. Among veterans screened for PCa, African American men had a 29% increased risk of PCa detection on a diagnostic prostate biopsy compared with White (hazard ratio, 1.29; 95% CI, 1.27-1.31; P < .001). African American men who received definitive primary treatment of PCa experienced a lower risk of metastasis (hazard ratio, 0.89; 95% CI, 0.83-0.95; P < .001). However, African American men who received nondefinitive treatment classified as “other” were more likely to develop metastasis (adjusted hazard ratio, 1.29; 95% CI, 1.17-1.42; P < .001). Using the actual rate of metastasis from veterans who received definitive primary treatment, a persistent residual metastatic burden for African American men was observed across all National Comprehensive Cancer Network risk groups (low risk, 4 vs 2 per 100 000; intermediate risk, 13 vs 6 per 100 000; high risk, 19 vs 9 per 100 000).
Conclusions and relevance: This cohort analysis found significant disparities in the incidence of localized and metastatic PCa between African American veterans and White veterans. This increased incidence is a major factor associated with the residual disparity in PCa metastasis observed in African American veterans compared with White veterans despite their nearly equal response to treatment.
Conflict of interest statement
Figures




Similar articles
-
Racial and Ethnic Differences in Prostate Cancer Epidemiology Across Disease States in the VA.JAMA Netw Open. 2024 Nov 4;7(11):e2445505. doi: 10.1001/jamanetworkopen.2024.45505. JAMA Netw Open. 2024. PMID: 39546308 Free PMC article.
-
Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018.JAMA Netw Open. 2020 Sep 1;3(9):e2018318. doi: 10.1001/jamanetworkopen.2020.18318. JAMA Netw Open. 2020. PMID: 32986109 Free PMC article.
-
Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?Urol Oncol. 2014 Jan;32(1):34.e9-18. doi: 10.1016/j.urolonc.2013.01.003. Epub 2013 Mar 15. Urol Oncol. 2014. PMID: 23506962 Free PMC article.
-
Mortality Disparities in Racial/Ethnic Minority Groups in the Veterans Health Administration: An Evidence Review and Map.Am J Public Health. 2018 Mar;108(3):e1-e11. doi: 10.2105/AJPH.2017.304246. Am J Public Health. 2018. PMID: 29412713 Free PMC article. Review.
-
Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies.Cancer Rep (Hoboken). 2021 Oct;4(5):e1340. doi: 10.1002/cnr2.1340. Epub 2021 Feb 17. Cancer Rep (Hoboken). 2021. PMID: 33599076 Free PMC article. Review.
Cited by
-
Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer.JAMA Netw Open. 2023 Oct 2;6(10):e2337272. doi: 10.1001/jamanetworkopen.2023.37272. JAMA Netw Open. 2023. PMID: 37819658 Free PMC article.
-
The hidden costs: a qualitative analysis exploring the experience of prostate cancer treatment-related side effects on sexual function and urinary incontinence among Black survivors and their caregivers.J Cancer Surviv. 2024 Oct 24. doi: 10.1007/s11764-024-01681-5. Online ahead of print. J Cancer Surviv. 2024. PMID: 39446292
-
Determinants of receipt of prostate cancer screening among men living with HIV enrolled in an urban HIV Clinic in the United States over the period of 2000-2020.Prev Med. 2024 Jul;184:108000. doi: 10.1016/j.ypmed.2024.108000. Epub 2024 May 10. Prev Med. 2024. PMID: 38735585 Free PMC article.
-
Regulation of Prostate Androgens by Megalin and 25-hydroxyvitamin D Status: Mechanism for High Prostate Androgens in African American Men.Cancer Res Commun. 2023 Mar 3;3(3):371-382. doi: 10.1158/2767-9764.CRC-22-0362. eCollection 2023 Mar. Cancer Res Commun. 2023. PMID: 36875158 Free PMC article.
-
Gastrointestinal cancers among Asian American and Pacific Islander populations.Lancet Reg Health Am. 2025 Jan 10;42:100989. doi: 10.1016/j.lana.2024.100989. eCollection 2025 Feb. Lancet Reg Health Am. 2025. PMID: 39877308 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical